文献速递核素与放射性配体治疗

在初步PSMA放射配体治疗研究中剂量学准确性对与治疗结局相关性的影响

Influence of dosimetry accuracy on the correlation with treatment outcome in a preliminary PSMA radiopharmaceutical therapy study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-12-20

该回顾性研究分析21例接受多周期177Lu-PSMA-617放射配体治疗的转移性去势抵抗性前列腺癌患者,比较标准多时间点剂量学与单时间点剂量学(Hänscheid近似法)与治疗结局及并发症风险的相关性。结果显示,尽管单时间点法在肿瘤和骨髓剂量学上存在平均百分比误差,但其与前列腺特异性抗原下降率和贫血分级的相关性与多时间点法无显著差异,两种方法的总剂量均对总生存有显著影响。

要点

  • 单时间点剂量学法与多时间点法在肿瘤剂量学上平均百分比误差高达36.44%,但与PSA下降率的相关性无显著差异。
  • 单时间点法与多时间点法的总剂量均对总生存有显著影响(风险比分别为1.05、3.41和8.06)。
  • 骨髓剂量学平均百分比误差低至-40.26%,但单时间点法与贫血分级的相关性与多时间点法无显著差异。

核心结论

  • 小队列的初步研究结果表明,临床简化方案降低的剂量学准确性可能不会削弱剂量学对临床治疗结局的预测价值。
  • 未来可能需要进行全面的系统性研究以确定临床可接受的剂量学准确性水平。

研究设计与样本

  • 回顾性研究,纳入21例诊断为转移性去势抵抗性前列腺癌并接受多周期177Lu-PSMA-617放射配体治疗的患者。
  • 对同一队列使用标准多时间点剂量学法和单时间点剂量学法(Hänscheid近似法)计算所有治疗周期的累积剂量学。
  • 分析剂量学与治疗结局(PSA下降率和总生存)及并发症风险(贫血分级)的相关性,并用Fisher Z转换检验评估相关性差异的统计学意义。

主要发现

  • 单时间点法与多时间点法在肿瘤剂量学上的平均百分比误差高达36.44%,但与PSA下降率的相关性无显著差异(多时间点法:rho=-0.39,p<0.001;单时间点法:rho=-0.46,p<0.001;Z=0.58,p=0.56)。
  • 单时间点法总剂量和多时间点法总剂量均对总生存有显著影响(单时间点法总剂量:风险比=1.05,p<0.05;对数转换的多时间点法总剂量:风险比=3.41,p<0.05;对数转换的单时间点法总剂量:风险比=8.06,p<0.05)。
  • 骨髓剂量学平均百分比误差低至-40.26%,但单时间点法与贫血分级的相关性与多时间点法无显著差异(多时间点法:rho=0.35,p<0.001;单时间点法:rho=0.40,p<0.001;Z=-0.39,p=0.70)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出该研究为初步研究且队列较小。
  • 原文结论提出未来可能需要进行全面的系统性研究以确定临床可接受的剂量学准确性水平。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Despite the potential of dosimetry in optimizing personalized radiopharmaceutical therapy (RPT), its limited clinical implementation impedes the development of simplified protocols for routine adoption. However, simplifications may introduce errors in dosimetry, prompting questions about their impact on clinical practice. MATERIALS AND METHODS: In this retrospective study, we analyzed data from 21 patients diagnosed with metastatic castration-resistant prostate cancer (mCRPC) who underwent multiple cycles of 177Lu-PSMA-617 RPT treatment. Cumulative dosimetry of all the treatment cycles was calculated using both the standard multi-time point dosimetry (MTPD) method and the single time-point dosimetry (STPD, Hänscheid approximation) method for the same cohort. Their correlations with treatment outcome (PSA decline rate and overall survival, OS) and complication risk (anaemia grade) were investigated. The Fisher's Z-Transformed test was performed to statistically evaluate the difference between the correlations. RESULTS: STPD showed a non-significant difference in correlation with PSA decline rate, despite a mean percentage error (MPE) of up to 36.44% in tumor dosimetry compared to MTPD (MTPD: rho = -0.39, p < 0.001; STPD: rho = -0.46, p < 0.001; Z = 0.58, p = 0.56). Both STPDtotal and MTPDtotal demonstrated a significant impact on OS (STPDtotal: Hazard Ratio = 1.05, p < 0.05, log-transformed MTPDtotal: Hazard Ratio = 3.41, p < 0.05, log-transformed STPDtotal: Hazard Ratio = 8.06, p < 0.05). Additionally, despite a MPE of up to -40.26% in bone marrow dosimetry, STPD showed a non-significant difference in correlation with anemia grade (MTPD: rho = 0.35, p < 0.001; STPD: rho = 0.40, p < 0.001; Z = -0.39, p = 0.70). CONCLUSION: The preliminary findings from a small cohort indicate that the reduced accuracy of a clinically simplified protocol may not diminish the clinical therapy outcome predictive value of dosimetry. Future thorough systematic investigations may be needed to determine the clinically acceptable level of accuracy for dosimetry.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Hu J, Seifert R, Karkampouna S, et al. Influence of dosimetry accuracy on the correlation with treatment outcome in a preliminary PSMA radiopharmaceutical therapy study. Eur J Nucl Med Mol Imaging. 2024. PMID: 39704811. doi:10.1007/s00259-024-07010-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。